Novel antagonist antibody to TLR3 blocks poly(I:C)-induced inflammation in vivo and in vitro

Cellular Immunology

Volumn 267, Issue 1, 2011, Pages 9-16

  Bunting, Rachel A ^a   Duffy, Karen E ^a   Lamb, Roberta J ^a   San Mateo, Lani R ^a   Smalley, Karen ^a   Raymond, Holly ^a   Liu, Xuesong ^a   Petley, Ted ^a   Fisher, Jamie ^a   Beck, Heena ^a   Flavell, Richard A ^b   Alexopoulou, Lena ^c   Ward, Christine K ^d  

^a CENTOCOR INC   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^d MEDIMMUNE   (United States)

Author keywords

Monoclonal antibody; Poly(I:C); TLR3

Indexed keywords

CNTO4685; CNTO5429; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G1; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; POLY(ISOBUTYL 2 CYANOACRYLATE); SCAFFOLD PROTEIN; TOLL LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; EMBRYO; FIBROBLAST; FLOW CYTOMETRY; GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; CELLS, CULTURED; HUMANS; INFLAMMATION; INTRACELLULAR SPACE; MACROPHAGES; MICE; MICE, INBRED C57BL; POLY I-C; TOLL-LIKE RECEPTOR 3;

RATTUS;

EID: 78651064825     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.10.008     Document Type: Article

References (32)

1. Imler J.L., Zheng L. Biology of Toll receptors: lessons from insects and mammals. J. Leukoc. Biol. 2004, 75:18-26.
2. Takeda K., Akira S. TLR signaling pathways. Semin. Immunol. 2004, 16:3-9.
3. Pasare C., Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect. 2004, 6:1382-1387.
4. Kopp E., Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr. Opin. Immunol. 2003, 15:396-401.
5. O'Neill L.A., Bryant C.E., Doyle S.L. Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 2009, 61:177-197.
6. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007, 13:552-559.
7. Ishii K.J., Uematsu S., Akira S. 'Toll' gates for future immunotherapy. Curr. Pharm. Des. 2006, 12:4135-4142.
8. Duffy K.E., Lamb R.J., San Mateo L.R., Jordan J.L., Canziani G., Brigham-Burke M., Korteweg J., Cunningham M., Beck H.S., Carton J., Giles-Komar J., Duchala C., Sarisky R.T., Mbow M.L. Down modulation of human TLR3 function by a monoclonal antibody. Cell. Immunol. 2007, 248:103-114.
9. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001, 413:732-738.
10. Kariko K., Ni H., Capodici J., Lamphier M., Weissman D. MRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 2004, 279:12542-12550.
11. McCartney S., Vermi W., Gilfillan S., Cella M., Murphy T.L., Schreiber R.D., Murphy K.M., Colonna M. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J. Exp. Med. 2009, 206:2967-2976.
12. Zhang S.Y., Jouanguy E., Ugolini S., Smahi A., Elain G., Romero P., Segal D., Sancho-Shimizu V., Lorenzo L., Puel A., Picard C., Chapgier A., Plancoulaine S., Titeux M., Cognet C., von Bernuth H., Ku C.L., Casrouge A., Zhang X.X., Barreiro L., Leonard J., Hamilton C., Lebon P., Heron B., Vallee L., Quintana-Murci L., Hovnanian A., Rozenberg F., Vivier E., Geissmann F., Tardieu M., Abel L., Casanova J.L. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007, 317:1522-1527.
13. Richer M.J., Lavallee D.J., Shanina I., Horwitz M.S. Toll-like receptor 3 signaling on macrophages is required for survival following Coxsackie virus B4 infection. PLoS One 2009, 4:e4127.
14. Wang T., Town T., Alexopoulou L., Anderson J.F., Fikrig E., Flavell R.A. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 2004, 10:1366-1373.
15. Gowen B.B., Hoopes J.D., Wong M.H., Jung K.H., Isakson K.C., Alexopoulou L., Flavell R.A., Sidwell R.W. TLR3 deletion limits mortality and disease severity due to Phlebovirus infection. J. Immunol. 2006, 177:6301-6307.
16. Hutchens M., Luker K.E., Sottile P., Sonstein J., Lukacs N.W., Nunez G., Curtis J.L., Luker G.D. TLR3 increases disease morbidity and mortality from vaccinia infection. J. Immunol. 2008, 180:483-491.
17. Le Goffic R., Balloy V., Lagranderie M., Alexopoulou L., Escriou N., Flavell R., Chignard M., Si-Tahar M. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog. 2006, 2:e53.
18. Cavassani K.A., Ishii M., Wen H., Schaller M.A., Lincoln P.M., Lukacs N.W., Hogaboam C.M., Kunkel S.L. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J. Exp. Med. 2008, 205:2609-2621.
19. Kim K.W., Cho M.L., Oh H.J., Kim H.R., Kang C.M., Heo Y.M., Lee S.H., Kim H.Y. TLR-3 enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis. Immunol. Lett. 2009, 124:9-17.
20. Brentano F., Kyburz D., Schorr O., Gay R., Gay S. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell. Immunol. 2005, 233:90-96.
21. Murray L.A., Knight D.A., McAlonan L., Argentieri R., Joshi A., Shaheen F., Cunningham M., Alexopolou L., Flavell R.A., Sarisky R.T., Hogaboam C.M. Deleterious role of TLR3 during hyperoxia-induced acute lung injury. Am. J. Respir. Crit. Care Med. 2008, 178:1227-1237.
22. Sugiura H., Ichikawa T., Koarai A., Yanagisawa S., Minakata Y., Matsunaga K., Hirano T., Akamatsu K., Ichinose M. Activation of Toll-like receptor 3 augments myofibroblast differentiation. Am. J. Respir. Cell Mol. Biol. 2009, 40:654-662.
23. Morishima H., Kajiwara K., Akiyama K., Yanagihara Y. Ligation of Toll-like receptor 3 differentially regulates M2 and M3 muscarinic receptor expression and function in human airway smooth muscle cells. Int. Arch. Allergy Immunol. 2008, 145:163-174.
24. Stowell N.C., Seideman J., Raymond H.A., Smalley K.A., Lamb R.J., Egenolf D.D., Bugelski P.J., Murray L.A., Marsters P.A., Bunting R.A., Flavell R.A., Alexopoulou L., San Mateo L.R., Griswold D.E., Sarisky R.T., Mbow M.L., Das A.M. Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice. Respir. Res. 2009, 10:43.
25. de St.Groth S.F., Scheidegger D. Production of monoclonal antibodies: strategy and tactics. J. Immunol. Methods 1980, 35:1-21.
26. Salem M.L., Diaz-Montero C.M., El-Naggar S.A., Chen Y., Moussa O., Cole D.J. The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naive recipient mice. Vaccine 2009, 27:549-557.
27. Sun J., Duffy K.E., Ranjith-Kumar C.T., Xiong J., Lamb R.J., Santos J., Masarapu H., Cunningham M., Holzenburg A., Sarisky R.T., Mbow M.L., Kao C. Structural and functional analyses of the human Toll-like receptor 3. Role of glycosylation. J. Biol. Chem. 2006, 281:11144-11151.
28. Case T.J. Invasion resistance arises in strongly interacting species-rich model competition communities. Proc. Natl. Acad. Sci. USA 1990, 87:9610-9614.
29. Xiao X., Zhao P., Rodriguez-Pinto D., Qi D., Henegariu O., Alexopoulou L., Flavell R.A., Wong F.S., Wen L. Inflammatory regulation by TLR3 in acute hepatitis. J. Immunol. 2009, 183:3712-3719.
30. Hardarson H.S., Baker J.S., Yang Z., Purevjav E., Huang C.H., Alexopoulou L., Li N., Flavell R.A., Bowles N.E., Vallejo J.G. Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H251-H258.
31. Matsumoto M., Funami K., Oshiumi H., Seya T. Toll-like receptor 3: a link between toll-like receptor, interferon and viruses. Microbiol. Immunol. 2004, 48:147-154.
32. Park B., Brinkmann M.M., Spooner E., Lee C.C., Kim Y.M., Ploegh H.L. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat. Immunol. 2008, 9:1407-1414.